Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17580298 | 1.00 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL18908171 | 0.87 | ACACB (0.44) | ACACBACACA | |
| SCHEMBL29642175 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL29700513 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL29354548 | 0.86 | ACACB (0.45) | ACACBACACA | |
| SCHEMBL14945397 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL14945398 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL21980409 | 0.86 | ACACB (0.45) | ACACBACACA | |
| SCHEMBL21816549 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL30901794 | 0.86 | ACACB (0.45) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904357-A1 | SPIRO COMPOUND AND MEDICAL USES THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| CN-111848678-A | Phosphorus-containing thienopyrimidine derivatives | 正大天晴药业集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| US-9988399-B2 | Bicyclic compounds as ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160108060-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-04-21 | — | — | US | disclosed |
| EP-2994138-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ACACA, COASY, ACACB | ACACB 3/4885ACACA 1/4885 |
| US-20160108060-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ACACA, COASY, ACACB | ACACB 3/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.